This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.
Get full access to this article
View all access options for this article.
References
1.
HeislerM, HamiltonG, AbbottA, ChengalaramA, KocejaT, GerkinR. Randomized double-blind trial of sublingual atropine vs. placebo for the management of death rattle. J Pain Symptom Manage.2013;45(1):14-22.
2.
KehlKA, KowalkowskiJA. A systematic review of the prevalence of signs of impending death and symptoms in the last 2 weeks of life. Am J Hosp Palliat Care. 2013;30(6):601-616.
3.
ProtusBM, GrauerPA, KimbrelJM. Evaluation of atropine 1% ophthalmic solution administered sublingually for the management of terminal respiratory secretions. Am J Hosp Palliat Care. 2013;30(4):388-392.
4.
ShinjoT, OkadaM. Atropine eyedrops for death rattle in a terminal cancer patient. J Palliat Med.2013;16(2):212-213.
5.
BascomPB. Inadvertent ophthalmic administration of atropine drops in a hospice patient. Am J Hosp Palliat Care. 2013;30(8):793-794.
